Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

QDEL - QuidelOrtho Corporation Последние новости | Finranks

Home

/

QDEL

Q

QuidelOrtho Corporation (QDEL)

NMS – Цена в реальном времени. Валюта: USD

11.12

+1.16 (11.65%)

При закрытии: May 12, 2026, 4:00 PM EDT

11.12

0.00 (0.00%)

До открытия: May 13, 2026, 4:00 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Hantavirus outbreak: these 3 stocks are poised to rip higher

Hantavirus outbreak: these 3 stocks are poised to rip higher

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.

QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y

QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y

QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates

QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates

QuidelOrtho (QDEL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago.

QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline

Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Видео

No Data

There is no data to display

Пресс-релизы

QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

Understanding and Addressing Syphilis Trends - and What's Being Missed

Understanding and Addressing Syphilis Trends - and What's Being Missed

SAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections. Hosted by Josh Casey, the episode features Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, who breaks down what CDC data reveals, why congenital syphilis continues to rise and how diagnostic strategies and healthcare workflows can close critical screening gaps, especially during pregnancy.

TTP Group Announces the Sale of LEX Diagnostics

TTP Group Announces the Sale of LEX Diagnostics

CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular.

QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics – – Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less – – Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year – SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.